News
Author: admin als-handoff
-
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on March 11, 2021
SEATTLE, Wash. and VANCOUVER, British Columbia / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its fourth quarter and year-end 2020 financial results and provide an update on the cytisinicline development program on Thursday,…
-
Achieve Life Sciences Announces Presentation of Data on Smoker and E-Cigarette User Attitudes and Perceptions on Quitting at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
SEATTLE, Wash. and VANCOUVER, British Columbia, February 24, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT…
-
Achieve Life Sciences to Present at the MicroCap Rodeo Winter Wonderland Conference on February 16, 2021
SEATTLE, Wash and VANCOUVER, British Columbia / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held…
-
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award
SEATTLE, Wash. and VANCOUVER, British Columbia, February 3, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations….
-
Achieve Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
SEATTLE, Wash. and VANCOUVER, British Columbia, January 7, 2021 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021. A webcast of the presentation will…